Breaking News on Global Pharmaceutical Technology & Manufacturing

Hot Topics > Lifecycle management

Lifecycle management

As R&D productivity declines and the age of blockbuster medicines reaches an end, the pharmaceutical industry is looking at ways to extend the profitable life of its products up to and beyond patent expiry.

Mutiple parameters are key to powder analysis, says Freeman

18-May-2009 -  Freeman Technologies, which showcased its FT4 Rheometer at Achema in Frankfurt, Germany, last week, says pharmaceutical powders are complex systems that require analysis of multiple parameters. 

Hospira calls time on US biogenerics delays

06-May-2009 -  Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings...

Sanofi seeks collaborators for €200m biotech plant

05-May-2009 -  French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolaunch project. 

Pfizer eyes FOBs and small to midsized deals

30-Apr-2009 -  Pfizer is monitoring opportunities in follow-on biologics and continuing to look for small to mid-sized deals as it plans for life without Lipitor, global revenues of which fell by 13...

Lilly & Amylin team up to create diabetes pen

30-Apr-2009 -  Eli Lilly and Amylin Pharmaceuticals are jointly developing an exenatide once weekly pen device, which should provide a more convenient way for diabetics to treat themselves.

Sanofi pulls plug on four Ph III drugs

29-Apr-2009 -  Sanofi-Aventis has halted development of four Phase III drugs in a “rigorous” pre-patent loss pipeline review that has also seen it drop four Phase II candidates and six Phase I...

Nanoparticles used to create topical Viagra rival

29-Apr-2009 -  Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis, according to research, reducing the side effects that can occur when taking drugs like Viagra.

Hovione shows off Irish API plant

23-Apr-2009 -  API maker Hovione’s manufacturing facility in Cork, Ireland was unveiled at an opening ceremony yesterday just two weeks after the previous owner, global drug giant Pfizer, formally handed over the...

Pfizer moves for Indian unit, following Novartis’ lead

15-Apr-2009 -  Pfizer is the latest company to seek greater control of its Indian subsidiary, falling into step with Swiss drug major Novartis which made a similar move late last month.  ...

Shire to close Owings Mills Adderall XR plant

08-Apr-2009 -  Biopharmaceuticals firm Shire will cease manufacture at its plant in Owings Mills, Maryland, US with the loss of 260 jobs in the latest stage of its plan to wind up...

Intelligent sorbents can save “6-12 months of development”

06-Apr-2009 -  The use of intelligent sorbents to improve product stability can save companies six to 12 months of development and boost revenues, according to Adrian Possumato, global director at Multisorb.

Altea inks deal to use Byetta with PassPort patch

02-Apr-2009 -  The search for more convenient diabetes treatments continues, with Altea Therapeutics reaching a $46m agreement with Eli Lilly and Amylin to develop a transdermal patch administering Byetta.

Flexibility is key for processing sector says Millipore

26-Mar-2009 -  Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.

GSK may move for Botox maker Allergan

25-Mar-2009 -  The pharmaceutical rumour mill is still spinning with the latest speculation that UK drug major GSK is interested in Botox manufacturer Allergan causing the US firm’s share price to leap...

Pharma mega mergers a boon for Patheon's restructuring service, says CEO

25-Mar-2009 -  The global economic downturn, impending blockbuster patent expiries and the wave of consolidation sweeping the pharmaceutical industry will drive demand for Patheon’s restructuring service according to CEO Wesley Wheeler. ...

Skin care firm Stiefel considers $4bn sale

23-Mar-2009 -  Dermatology drug specialist Stiefel Laboratories may be looking for a Big Pharma buyer according to various media reports.

Actavis moves towards Japanese generics market

17-Mar-2009 -  Actavis’ JV with Japan’s Aska Pharmaceuticals opens up the non-branded sector of the world’s second largest drug market  

Merck moves for Schering in $41bn mega-merger

10-Mar-2009 -  The year of the mega-merger continues with Merck & Co’s move to buy Schering-Plough for $41.1bn, with the intention of boosting its pipeline, entering new markets and creating a “powerful...

US approvals provide some respite for Ranbaxy

09-Mar-2009 - Two approvals in a week for drugs made at Ranbaxy’s New Jersey OHM Laboratories subsidiary have eased the generics firm’s North American regulatory woes and strengthened its position in the...

Piramal won’t “dilute ownership,” or comment on Sanofi rumours

04-Mar-2009 -  Indian generics firm Piramal Healthcare says it "has no intention to dilute current ownership levels," but has not commented on rumours that it is in talks with French firm Sanofi...

Pfizer pulls plug on two Ph III drugs

25-Feb-2009 -  Pfizer’s primary care business unit has dropped two Phase III candidates, further reducing the drug giant’s product pipeline and raising more questions about its R&D decisions. ...

SAFC's Q4 hit by lack of visibility in drug sector

16-Feb-2009 -  SAFC’s fourth quarter performance was hurt by dip in demand from big pharma in the US and Europe combined with lower sales to the chemical industry, according to parent company...

King feels pain of Skelaxin defeat and Remoxy delays

05-Feb-2009 -  King Pharmaceuticals has unveiled plans to reduce its workforce by 22 per cent in a bid to further reduce costs after the US District Court decision to invalidate patents protecting...

Adventrx cuts its workforce again

13-Jan-2009 -  US drugmaker Adventrx Pharmaceuticals is reducing its workforce to just 14 employees in a bid to preserve cash and refocus efforts on bioequivalence programmes for its lead candidates. 

Orion tightens its belt with 205 job cuts

08-Jan-2009 -  Finnish drugmaker Orion is to follow through on plans to cut its R&D workforce and shed 205 employees to sure up operations as generic pressure mounts on its leading Parkinson’s...

Key Industry Events

Interphex 2014

New York, NY 10001 / Conference and exhibition

Read more

Access all events listing